Log In / Register
New data on efficacy and stability of Mavenclad
17 September, 2019
Merck announced the presentation of new data proving the long-term efficacy and stability of Mavenclad (HPBCD formulated cladribine) against relapsing forms of multiple sclerosis.
Read more on Cyclodextrin News blog
BACK TO NEWS